Quick navigation menu :

  1. Go to the content
  2. Go to main section's menu
  3. Go to Search tool
  4. Go to Help menu
  5. Go to modules
  6. Go to the list of keyboard shortcuts

Help menu :

  1. Sanofi Worldwide |
     
  2. Our Web Sites |
     
  3. Global Business Websites |
     
  4. Contact Us |
  5. Sitemap |
  6. Help
  1. Font size

    Reduce font size Increase font size  
 
 

Your Health

Contact Us

Sanofi Ireland Ltd.

18 Riverwalk
Citywest Business Campus
Dublin 24

Tel : + 353 (0)1 403 5600

Content :

Oncology

Oncology

Our Sanofi oncology division plays a daily role in bringing hope into the lives of Irish cancer sufferers and their families with drugs, such as Taxotere and Eloxatin, treating Ireland’s most prevalent solid cancers – i.e. breast cancer, lung cancer, colorectal cancer and prostate cancer

 

Cancer concerns all of us. In 2002, more than 21,000 new cases of cancer were diagnosed in Ireland and nearly 8,000 Irish people died from cancer (National Cancer Registry data – 1994-2002).

Lung, colon and gastric cancers are among the five most common cancers worldwide, with breast cancer in women and prostate cancer in men. Cancer growth is continuing at an alarming rate worldwide. In industrialized countries, the elderly are not the only victims: cancer is the leading cause of death in people under 65 years.

However, therapeutic progress, prevention by more healthy lifestyle and detection should finally help reduce the number of deaths from certain cancers. Research into the treatment of different types of cancer is one of the most advanced specialisms of modern medicine. At Sanofi our existing portfolio is one that we are proud of and we also have an incredibly strong oncology pipeline that we are confident will drive progress in cancer treatment for many years to come.

  • Eloxatin™ (oxaliplatin for injection)

  • Taxotere® (docetaxel) for injection concentrate

Module :